Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

Table 1

A brief summary of the CML treatment schedule including the drug, dosage, duration, and response/event.

Drug	Dose	Duration	Response/event
Bosutinib	400 mg/day	14 months	Complete cytogenetic response
Imatinib Mesylate	400 mg/day	2 months	Hematologic adverse event (pancytopenia)
Nilotinib	2 × 400 mg/day	4 months	Molecular relapse
Dasatinib	100 mg/day	3 months	No molecular response, minor cytogenetic response
Dasatinib + IFN 2a	140 mg/day + 3 MU/day	3 months	Blastic crisis (BP)
Dasatinib	100 mg/day	1 month	Leukemic transformation